Get the Daily Brief
Latest Biotech News
FDA drafts MRD guidance: Faster paths for multiple‑myeloma drugs
The U.S. Food and Drug Administration issued draft guidance describing how measurable residual disease (MRD) negativity and complete response could support accelerated approval pathways in...
Cellular Origins, Fresenius complete CGT automation milestone
Cellular Origins and Fresenius Kabi completed integration of Fresenius Kabi’s Cue R Cell Processing System into Cellular Origins’ Constellation R CGT robotic manufacturing platform, marking the...
Nanopore cytogenetics: 4bases launches hospital pilots in Italy
Swiss biotech 4bases and researchers from the University of Florence launched clinical pilot studies in two Italian hospitals to validate nanopore sequencing–based cytogenetics for real‑time...
Neok Bio wins FDA IND for bispecific ADC NEOK‑001
Neok Bio announced FDA clearance of an investigational new drug application for NEOK‑001, a bispecific antibody–drug conjugate, clearing the way for a phase I trial in solid tumors. The company...
Nvidia and Lilly Launch $1B AI Lab — Accelerate Drug Discovery
Nvidia and Eli Lilly announced a $1 billion joint laboratory in the San Francisco Bay Area to deploy large‑scale AI across drug discovery workflows. The partnership will co‑locate teams and...
Corxel Raises $287M — Funds Global Oral GLP‑1 Trials
Corxel Pharmaceuticals closed a large financing to advance an oral GLP‑1 candidate into global phase 2/3 development for obesity and metabolic indications. The Series D financing, reported at $287...
BMS Signs $850M Janux Pact — Tumor‑Activated T‑Cell Engager Push
Bristol Myers Squibb inked an alliance with Janux Therapeutics around Janux’s tumor‑activated T‑cell engager platform, committing $50 million up front and up to $800+ million in development and...
Relacorilant Shows 35% Mortality Drop — Corcept Readies FDA Bid
Corcept Therapeutics reported phase III data showing its selective glucocorticoid receptor antagonist relacorilant reduced risk of death by 35% when added to chemotherapy in platinum‑resistant...
FDA Issues Draft MRD Guidance — Myeloma Endpoints Evolve
The U.S. FDA released draft guidance endorsing measurable residual disease (MRD) negativity and complete response as potential accelerated approval endpoints for multiple myeloma, signaling a...
Regulators Clear New Diagnostics Paths — Liquid Biopsy and MCED Move
Guardant Health secured FDA approval for its Guardant360 CDx blood test as a companion diagnostic for Pfizer’s Braftovi (encorafenib) plus cetuximab and chemotherapy in BRAF V600E‑mutant...
FDA Clears INDs for Two Tumor‑Targeted Programs — Clinic Start Imminent
Neok Bio received FDA IND clearance for NEOK‑001, a bispecific antibody‑drug conjugate, enabling a phase I solid tumor trial. Avacta also cleared an IND for AVA‑6103, a fibroblast activation...
Nanorobots and Oligodendrocyte Biology Advance Neural Repair Strategies
Researchers unveiled camouflaged nanorobots that direct macrophage behavior to boost neural tissue repair, reporting preclinical improvements in regeneration metrics. The work combines targeted...
Simpler Alzheimer Tests Move Forward — Plasma and Finger‑Prick Trials
A streamlined plasma amyloid‑beta assay demonstrated improved sensitivity and resource efficiency in preclinical and early clinical cohorts, offering a lower‑cost biomarker route for Alzheimer’s...
MYC’s RNA Role and Plasticity States Expose New Cancer Vulnerabilities
A Cell paper from teams at the University of Würzburg and MIT reported that high levels of MYC bind nascent RNA, recruit the nuclear exosome, and clear R‑loop RNA–DNA hybrids—silencing innate...
Nvidia and Lilly Launch $1 Billion AI Drug Lab
Nvidia and Eli Lilly announced a $1 billion collaboration to build an AI-powered drug discovery lab in the San Francisco Bay Area. The partners will combine Nvidia’s computing and AI...
Pharma Bets on AI Platforms: Deals Flood In
Industry reporting documented a flurry of early-2026 platform deals between pharma giants and AI startups, with partnerships spanning biologics design, small-molecule discovery and...
Corxel Raises $287M — Pushes Oral GLP‑1 Global
Corxel Pharmaceuticals closed a $287 million financing round to fund global development of its oral GLP‑1 candidate licensed from Vincentage. The financing will support phase 2/3 studies and...
Bristol Myers Backs Janux — $50M Upfront, $850M Deal Possible
Bristol Myers Squibb struck a collaboration and exclusive worldwide license with Janux Therapeutics to develop a tumor‑activated T‑cell engager, providing $50 million upfront and up to $800–850...
Relacorilant Cuts Death Risk: Corcept Eyes $2.1B Market
Corcept reported that relacorilant, its oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in a phase III ovarian cancer study, meeting overall‑survival and...
FDA Drafts MRD Guidance: Faster Paths for Myeloma Drugs
The U.S. Food and Drug Administration issued draft guidance allowing measurable residual disease (MRD) negativity and complete response rates to support accelerated approvals in multiple myeloma....